RESUMEN
Intorduction:The present study was conducted in the departments of Anatomy, Radiology and Paediatrics at a General Public Charitable Hospital, Mumbai. Method: The study group consisted of 160 children of both sexes, who were referred to the Radiology department for ultrasonography. Out of these 160 chidren, 80 underwent sonography for abdominal and/or pelvic problems unrelated to the spleen and 80 children were suffering from medical disorders related to spleen i.e. 55 patients of thalassemia major, 13 patients of malaria, 9 patients of typhoid and 3 patients of portal hypertension. The splenic length was measured by using a commercially available real time ultrasound system with a TOSHIBA ECOCEE USG SYSTEM particularly by using the convex probe. Result: In the present study in abnormal spleen group, there is a strong correlation between weight and splenic size, and between age and splenic size, there is a partial correlation between height and the splenic size. In all the children with clinically obvious splenomegaly, the splenic length exceeded at least 2 cm than the normal splenic length at that particular age.Conclusion : This study shall stand as a good reference to Radiologists, Paediatricians, Haematologists and Physicians in an undiagnosed and complicated cases and will also helpful to determine the mode of treatment in thalassemia major with splenomegaly.
RESUMEN
Janus Activated Kinase (JAK) 2 plays an important role in the pathogenesis of myelofibrosis (MF). Ruxolitinib (INCB018424, Jakafi) is a potent dual JAK1 and JAK2 inhibitor. In November 2011, it became approved by the US FDA for the treatment of intermediate or high-risk MF. This review shall outline the role of Ruxolitinib in the current management of MF and its potential future.